23andMe's Fatal Flaw | Defying Gravity? | 2

Plagued by low sales of its genetic tests, 23andMe adopts a bold new plan: slash prices and enter the pharmaceutical industry. But with investors nervous, can CEO Anne Wojcicki keep the show going long enough to make her DNA dream pay off?Be the first to know about Wondery’s newest podcasts, curated recommendations, and more! Sign up now at https://wondery.fm/wonderynewsletterListen to Business Wars on the Wondery App or wherever you get your podcasts. Experience all episodes ad-free and be the first to binge the newest season. Unlock exclusive early access by joining Wondery+ in the Wondery App or on Apple Podcasts. Start your free trial today by visiting wondery.com/links/business-wars/ now. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.